News | August 11, 2022
IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Subscribe To Our Newsletter & Stay Updated
